Total cholesterol decrease associates with higher mortality in chronic heart failure

20 May 2023 (08:00 - 20:00)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Maria Rocha

Sao Joao Hospital, Porto (Portugal)

5 More presentations in this session

Presentation thumbnail

Safety, pharmacokinetics, and pharmacodynamics of AZD3427, a functionally selective long acting relaxin mimetic agonist of the RXFP1 receptor

Professor M. Ufnal (Warsaw, PL)

Abstract Slides

Presentation thumbnail

Hypoalbuminemia increases the time to euvolemia in heart failure patients

Doctor I. Fialho (Lisbon, PT)

Abstract Slides

Presentation thumbnail

A budget impact analysis of empagliflozin for heart failure patients with full spectrum of ejection fraction in South Korea

Doctor J. Youn (Seoul, KR)

Abstract Slides

Presentation thumbnail

Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: insights from the CANVAS Program and CREDENCE trial

Doctor A. Sharma (Montreal, CA)

Abstract Slides

Presentation thumbnail

Long-acting relaxin (LY3540378) demonstrates improved renal hemodynamics response in preclinical and clinical studies

Doctor X. Wang (Indianapolis, US)

Abstract Slides

Access the full session

Session thumbnail

Chronic heart failure - pharmacotherapy 6

The Event

Event poster

Heart Failure 2023

20 May - 23 May 2023

You may be interested in

Congress Presentation

Breaking the barriers in guideline-directed medical therapy implementation in heart failure - discussion

Congress Presentation

The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?

Congress Session

Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources